| Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia. | |
| | |
MedLine Citation:
|
PMID: 20550538 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
OBJECTIVE: Cabergoline is a highly effective medical treatment for patients with hyperprolactinaemia. There is an increased risk of valvular heart disease in patients receiving cabergoline for Parkinson's disease. This study examined whether cabergoline treatment of hyperprolactinaemia is associated with a greater prevalence of valvulopathy. DESIGN: Cross-sectional, two-dimensional echocardiographic study performed by a single echocardiographer. PATIENTS: Seventy-two patients (median age 36 years, 19 men) receiving cabergoline for hyperprolactinaemia, and 72 controls prospectively matched for age, sex and cardiovascular risk factors. Measurements Assessment of valvular mobility, regurgitation and morphology. RESULTS: Median cumulative dose exposure for cabergoline was 126 (58-258) mg, and patients had received cabergoline for 53 (26-96) months. The frequency of mild mitral regurgitation was identical (5/72, 7%) in patient and control groups. Mild aortic regurgitation was not significantly different between groups (4/72 [controls] vs 2/72 [patients], P = 0.681). There was only one case of tricuspid regurgitation, which was mild and observed in a cabergoline-treated patient. Nodular thickening of the right coronary cusp, noncoronary cusp or left coronary cusp of the aortic valve was observed at a similar frequency in both groups. There were no cases of extensive thickening of any valvular leaflet. CONCLUSION: Our data demonstrates that there is no association between cabergoline treatment for hyperprolactinaemia and valvulopathy. This study therefore supports continued use of low-dose cabergoline for patients with hyperprolactinaemia. |
| | |
Authors:
|
Tricia Tan; Ines Z Cabrita; Davina Hensman; Joanna Grogono; Waljit S Dhillo; Kevin C Baynes; Joseph Eliahoo; Karim Meeran; Stephen Robinson; Petros Nihoyannopoulos; Niamh M Martin |
Related Documents
:
|
6872198 - Mitral valvuloplasty: a learning curve. 4007138 - Elastin and collagen in the aortic wall: changes in the marfan syndrome and annuloaorti... 12931108 - Temporal variations in effective orifice area during ejection in patients with valvular... 660748 - Posterior urethral valves managed by cutaneous ureterostomy with subsequent ureteral re... 9372668 - Empyema thoracis and lung abscess caused by viridans streptococci. 19786778 - Performance of fdg pet for detection of alzheimer's disease in two independent multicen... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2010-06-09 |
Journal Detail:
|
Title: Clinical endocrinology Volume: 73 ISSN: 1365-2265 ISO Abbreviation: Clin. Endocrinol. (Oxf) Publication Date: 2010 Sep |
Date Detail:
|
Created Date: 2010-08-27 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0346653 Medline TA: Clin Endocrinol (Oxf) Country: England |
Other Details:
|
Languages: eng Pagination: 369-74 Citation Subset: IM |
Affiliation:
|
Division of Diabetes, Endocrinology and Metabolism, Department of Medicine, Imperial College, London, UK. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Relationships between dimethylarginine and the presence of vertebral fractures in type 2 diabetes me...
Next Document: Prenatal dexamethasone use for the prevention of virilization in pregnancies at risk for classical c...